<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DESLORATADINE</span><br/>(des-lor-a-ta'deen)<br/><span class="topboxtradename">Clarinex, </span><span class="topboxtradename">Clarinex Reditabs<br/></span><b>Classifications:</b> <span class="classification">antihistamine, non-sedating</span>; <span class="classification">h<sub>1</sub>-receptor antagonist</span><br/><b>Prototype: </b>Loratadine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg tablets; 2.5 mg, 5 mg orally dissolving tablets; 0.5 mg/mL syrup</p>
<h1><a name="action">Actions</a></h1>
<p>A long-acting, nonsedating antihistamine with selective H<sub>1</sub> receptor antagonist properties. The drug reduces human mast cell release of the inflammatory cytokines. Therefore, it also
         exhibits antiallergic effects.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>It is more potent than loratadine as an antagonist at H<sub>1</sub> receptors. Desloratadine is effective in controlling allergic rhinitis and inhibiting histamine-induced wheals and flare
         (hives).
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of seasonal or perennial allergic rhinitis and idiopathic urticaria.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to desloratadine or loratadine; neonates; pregnancy (category C); lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal and hepatic insufficiencies; bladder neck obstruction or urinary retention; prostatic hypertrophy; glaucoma. Safety
         and efficacy in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Allergic Rhinitis, Idiopathic Urticaria</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 5 mg q.d.<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/><span class="rdage">Adult::</span> <span class="rdroute"> PO</span>  Cl<sub>cr</sub> <br/><span class="impairmenttitle">Hepatic Impairment</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 5 mg every other day<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Note that drug should be given q.o.d. to patients with significant renal or hepatic impairment.</li>
<li>Store between 2°25° C (36°77° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Pharyngitis, fatigue, flu-like symptoms, myalgia. <span class="typehead">CNS:</span> Somnolence, dizziness. <span class="typehead">GI:</span> Dry mouth, nausea, dry throat. <span class="typehead">Urogenital:</span> Dysmenorrhea. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Well absorbed. <span class="typehead">Peak:</span> 3 h. <span class="typehead">Distribution:</span> 8589% protein bound. <span class="typehead">Metabolism:</span> Extensively metabolized in liver to 3-hydroxydesloratadine, an active metabolite. <span class="typehead">Elimination:</span> Excreted equally in urine and feces. <span class="typehead">Half-Life:</span> 27 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Assess carefully for and report distressing or dangerous S&amp;S that occur after initiation of the drug. A variety of adverse
            effects, although not common, are possible. Some are an indication to discontinue the drug.
         </li>
<li>Monitor cardiovascular status and report significant changes in BP and palpitations or tachycardia.</li>
<li>Lab tests: Monitor periodically renal and liver function tests.</li>
<li>Concurrent drugs: Monitor ECG when used in combination with any other drug that can increase blood level of desloratidine
            in patients with preexisting cardiac disease.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Drug may cause significant drowsiness in older adult patients and those with liver or kidney impairment.</li>
<li>
            							Note: Concurrent use of alcohol and other CNS depressants may have an additive effect.
            						
         </li>
<li>Do not take this drug more often than every other day if you have renal impairment.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>